Study guide

12.2 Exploratory, Confirmatory and Therapeutic-Use Studies

ACRP CCRA Certified Clinical Research Associate Study Guide 2026 Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Format, Eligibility and Registration

1.1 Exam Format, Eligibility and Current References 1.2 Registration, Fees and Candidate Decisions

2 Chapter 2: CRA Responsibilities and Study Planning

2.1 The CRA Role, Data Integrity and Product Oversight 2.2 Official Blueprint and Study Strategy

3 Chapter 3: Protocols, Endpoints and Trial Design

3.1 Protocol Elements and Endpoint Hierarchy 3.2 Endpoint Interpretation and Eligibility Rationale 3.3 Eligibility Verification and Trial Designs

4 Chapter 4: Bias Control, Blinding and Product Information

4.1 Bias, Randomisation and Comparator Controls 4.2 Unblinding and Investigator Brochure Content 4.3 Reference Safety Information and IB Updates

5 Chapter 5: Estimands and Device Instructions

5.1 Estimands and Intercurrent Events 5.2 Device Instructions, Configuration and Training

6 Chapter 6: Ethical Foundations and Independent Oversight

6.1 Ethical Foundations and the 2024 Declaration of Helsinki 6.2 Vulnerability, Voluntariness and Compensation 6.3 IRB/IEC Composition and Independent Review

7 Chapter 7: Ethics Communication and Informed Consent

7.1 Ethics Reporting, Approval Status and Version Control 7.2 Informed Consent Information and Meaningful Choice 7.3 Consent Documentation, Special Circumstances and Updates

8 Chapter 8: Recruitment, Retention and Confidentiality

8.1 Ethical Eligibility, Recruitment and Retention 8.2 Privacy, Confidentiality and Appropriate Access

9 Chapter 9: Safety Definitions and Classification

9.1 Adverse Event Definitions and Actual Life-Threatening Risk 9.2 Seriousness, Severity and Medical Importance 9.3 Causality, Expectedness and Reference Safety Information

10 Chapter 10: Safety Detection, Reporting and Oversight

10.1 Detecting Events, AESIs and Collection Windows 10.2 Expedited Reporting and the Sponsor Awareness Clock 10.3 Immediate Site Reporting and Independent Safety Oversight

11 Chapter 11: Follow-Up, Adherence and Conflicts

11.1 Safety Communications, Reconciliation and Follow-Up 11.2 Adherence, Discontinuation and Participant Choice 11.3 Conflicts of Interest and Prorated Payments

12 Chapter 12: Development Stages and Product Management

12.1 Nonclinical Background and Human Pharmacology 12.2 Exploratory, Confirmatory and Therapeutic-Use Studies 12.3 Product Storage, Labelling and Excursion Response

13 Chapter 13: Accountability, Integrity and Regulatory Status

13.1 Product Accountability and Adherence Calculations 13.2 Potential Fraud, Misconduct and Evidence Preservation 13.3 Submissions, Authorisation Status and Trial Reporting

14 Chapter 14: Current GCP Principles and Delegation

14.1 The Eleven Current GCP Principles 14.2 Proportionality and Investigator Oversight 14.3 Delegation, Qualifications and Task Authority

15 Chapter 15: Oversight, Protocol Control and Amendments

15.1 Clinical Oversight and Immediate-Hazard Changes 15.2 Deviation Classification and Resolution

16 Chapter 16: Implementation and Trial Responsibilities

16.1 Amendment Implementation and Communication 16.2 Sponsor, Investigator and Service-Provider Roles

17 Chapter 17: Quality Planning, Root Causes and CAPA

17.1 Quality Planning and Risk Management 17.2 Root Cause Analysis and CAPA Design 17.3 CAPA Implementation and Effectiveness Verification

18 Chapter 18: Risk Assessment and Monitoring Methods

18.1 Risk Assessment and Centralised Surveillance 18.2 Monitoring Methods and Source Review

19 Chapter 19: Quality Metrics, Plans and Communication

19.1 KRIs, Acceptable Ranges and Trial-Level Quality 19.2 Monitoring Plans, Co-Monitoring and Communication

20 Chapter 20: Site Qualification and Readiness

20.1 Site Qualification and Investigator Capacity 20.2 Recruitment Feasibility and Evidence-Based Site Selection 20.3 Site Readiness and Activity-Specific Release

21 Chapter 21: Initiation, Equipment and Supplies

21.1 Initiation Training and Readiness Walkthroughs 21.2 Equipment, Maintenance and Study Supplies

22 Chapter 22: Samples, Diagnostics and Financial Feasibility

22.1 Specimens, Diagnostic Results and Rater Quality 22.2 Contracts, Budgets and Operational Feasibility

23 Chapter 23: Interim Monitoring and Reporting

23.1 Interim Visit Preparation and Consent Review 23.2 Monitoring Eligibility, Safety and Products 23.3 Investigator Debrief and Monitoring Reports

24 Chapter 24: Essential Records, Audits and Findings

24.1 Essential Records and Site/Sponsor Reconciliation 24.2 Version History, Resolution Evidence and Noncompliance 24.3 Audits, Inspections and Closure Planning

25 Chapter 25: Close-Out, Retention and Destruction

25.1 Close-Out, Archiving and Continuing Obligations 25.2 Retention, Destruction and Long-Term Access

26 Chapter 26: Source Records and Good Documentation

26.1 Source Records and Foundational ALCOA Principles 26.2 Good Documentation, Completeness and Corrections 26.3 Source Access, Certified Copies and Context

27 Chapter 27: Electronic Systems, Metadata and Queries

27.1 EDC Design and Fit-for-Purpose Systems 27.2 Audit Trails, Electronic Outcomes and Device Choice 27.3 Queries, Coding and Supported Clinical Meaning

28 Chapter 28: Dataset Finalisation and Critical Data

28.1 Safety Reconciliation and Dataset Finalisation 28.2 Critical Data, Acquisition Tools and Interim Findings

12.2 Exploratory, Confirmatory and Therapeutic-Use Studies

Key Takeaways Explain This Topic AI

ICH E8(R1) emphasises study objectives rather than a rigid development sequence.

Sample size, population and duration depend on the question and product.

Therapeutic-use studies can address longer-term safety and performance after authorisation.

Last updated: October 2026

Exploratory, Confirmatory and Therapeutic-Use Studies

Phase I trials present unique monitoring demands. The CRA must verify:

Precise timestamping of dense pharmacokinetic blood collection tubes, protocol adherence to centrifugation protocols, and temperature-verified bioanalytical cold-chain storage.

Continuous cardiac telemetry monitoring, real-time vital signs surveillance, and adherence to mandatory stopping rules.

Strict compliance with pre-dose fasting, fluid restriction, and standardized nutritional intake schedules.

Accurate reporting of all adverse events regardless of perceived causality, capturing subtle physiological shifts in healthy volunteers.

Phase II: Therapeutic Exploratory and Dose Selection

Phase II trials typically explore treatment effects in participants who suffer from the specific disease or clinical condition the drug is designed to treat.

Sub-Phases: IIa vs. IIb

Phase II clinical development is classically subdivided into exploratory and dose-ranging studies:

Phase IIa (Proof-of-Concept [POC]): Exploratory studies designed to assess whether the compound demonstrates genuine biological activity and preliminary clinical efficacy in the target disease population. Phase IIa confirms target engagement and evaluates short-term tolerability.

Phase IIb (Dose-Ranging and Regimen Optimization): Rigorous, randomized, multi-arm trials comparing various dose levels and dosing schedules against placebo or active controls. The primary goal is constructing the dose-response curve, establishing the Minimum Effective Dose (MED), and selecting the optimal dosing regimen that maximizes therapeutic response while minimizing toxicities to advance into Phase III.

Endpoints and Statistical Considerations

Phase II trials frequently evaluate validated surrogate endpoints or biomarker outcomes (e.g., reductions in circulating viral load, changes in glycated hemoglobin, or tumor shrinkage according to RECIST criteria) alongside clinical safety. Because Phase II trials evaluate efficacy signals, statistical analyses are exploratory, and endpoints are carefully scrutinized to determine whether the sponsor will commit the substantial capital required for Phase III pivotal development.

Phase III: Therapeutic Confirmatory and Pivotal Trials

Phase III trials—frequently referred to as "pivotal investigations"—are designed to provide definitive confirmation of clinical efficacy and safety across diverse, real-world patient cohorts.

Design Rigor and Regulatory Significance

Sample Size and Scope: Sample size and site count depend on the scientific question and population.

Regulatory Mandate: Demonstrating statistically significant, clinically meaningful superiority (or non-inferiority/equivalence) against existing standard-of-care treatments or placebo in Phase III serves as the primary scientific foundation for marketing applications submitted to global regulatory agencies, including the US Food and Drug Administration (FDA New Drug Application [NDA] or Biologics License Application [BLA]) and the European Medicines Agency (EMA Marketing Authorisation Application [MAA]).

Statistical Architecture: Confirmatory trials often use prospective randomised designs, with blinding when feasible. Sample size calculations are powered as specified by the design to detect pre-specified differences on primary clinical outcomes (e.g., overall survival, stroke recurrence, or major cardiovascular events) under prespecified error control.

CRA Monitoring Challenges in Phase III

In Phase III trials, CRAs encounter significant operational complexity:

Managing wide variations in standard-of-care medical practices and electronic health record systems across international jurisdictions.

Safeguarding allocation concealment and investigational product blinding across high-volume site pharmacies.

Coordinating rapid source data verification (SDV) and source data review (SDR) under aggressive interim analysis and database lock timelines.

Auditing high-volume adverse event reports and ensuring that Serious Adverse Events (SAEs) are escalated immediately according to the protocol.

Phase IV: Therapeutic Use and Post-Marketing Surveillance

Phase IV investigations occur after an investigational drug or biologic has received regulatory marketing authorization and entered commercial distribution.

Post-Marketing Commitments & Real-World Evidence (RWE)

While Phase III trials establish clinical efficacy in controlled cohorts, they are limited by finite sample sizes and strict exclusion criteria. Phase IV studies evaluate the approved product in broad, unselected patient populations to:

Detect rare adverse drug reactions (ADRs occurring at frequencies of < 1 in 10 , 000 < 1\text{ in }10,000 < 1 in 10 , 000 patients) that cannot be detected in Phase III cohorts.

Assess long-term clinical safety, cumulative toxicities, and chronic survival outcomes over years or decades.

Evaluate drug-drug and drug-disease interactions in polymedicated geriatric patients and individuals with multi-organ comorbidities.

Support health economics and outcomes research (HEOR), patient registries, and expanded indications.

Devices and development objectives

The ECO includes product/device instructions and traceability. Device investigations can involve feasibility learning, design refinement and confirmatory evaluation rather than a literal Phase I–IV drug sequence. Understand the scientific question, intended use, operator dependence and participant safeguards. ICH E6 concerns investigational medicinal products; specialised device laws and standards are workplace context and are not additional CCRA examination references.

A device study might require a defined model and software version, operator training, procedural documentation, accountability and instructions for handling a malfunction or explant. The monitor verifies those trial-specific requirements, preserves traceability and escalates a defect promptly. Do not infer a national risk classification, approval pathway or universal reporting deadline from a short clinical vignette.

Official sources

Checked October 18, 2026: ICH E6(R3), Principles and Annex 1 , ICH E8(R1) , ACRP CCRA Exam Content Outline .